Showing results (21-30 of 52) with videos related to
Sort By:
Pageof 6
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2022
[Experience with BD EleVationTM in Vacuum-Assisted Biopsy]Sae Ishihara, Shinichiro Kashiwagi, Yuko Kawano, et al.Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancerShinichi Kimura, Taishi Harada, Kayo Ijichi, et al.Frontiers in Immunology|June 12, 2023
Tfl deletion induces extraordinary Cxcl13 secretion and cachexia in VavP-Bcl2 transgenic miceKentaro Minagawa, Kanako Wakahashi, Chie Fukui, et al.International Journal of Hematology|July 14, 2011
Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantationKanako Wakahashi, Motohiro Yamamori, Kentaro Minagawa, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2022
[A Case of Liver Abscess during Treatment for Abemaciclib-Induced Interstitial Lung Disease]Asuka Komoda, Shinichiro Kashiwagi, Yuko Kawano, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2021
[Effectiveness of Atezolizumab Combination Therapy for PD-L1(SP142)Positive Lung and Breast Double Cancer-A Case Report]Yuka Asano, Shinichiro Kashiwagi, Yuko Kawano, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2021
[A Case of Cervical Metastasis from Breast Cancer]Yuko Kawano, Wataru Goto, Shinichiro Kashiwagi, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2021
[Clinical Significance of Inflammatory Markers in Recombinant Human-Soluble Thrombomodulin Therapy for DIC in Solid Tumors]Akimichi Yabumoto, Shinichiro Kashiwagi, Yuka Asano, et al.Blood|January 29, 2021
FGF-23 from erythroblasts promotes hematopoietic progenitor mobilizationShinichi Ishii, Tomohide Suzuki, Kanako Wakahashi, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2021
[A Case in Which Re-Administration of Pertuzumab/Trastuzumab with Eribulin Therapy Was Useful for Recurrent HER2 Breast Cancer]Rika Kouhashi, Shinichiro Kashiwagi, Yuko Kawano, et al.Pageof 6